Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | RECQL | P46063 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | CASP1 | P29466 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | CASP7 | P55210 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.75 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dactinomycin SCHEMBL13659669 | 0.87 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| Dactinomycin SCHEMBL27304406 | 0.87 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| Dactinomycin SCHEMBL26186613 | 0.87 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| Dactinomycin SCHEMBL6939686 | 0.87 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| Dactinomycin SCHEMBL20770348 | 0.86 | GRB2 (0.70) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| Dactinomycin SCHEMBL2790145 | 0.86 | GRB2 (0.99) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| Dactinomycin SCHEMBL28168861 | 0.86 | GRB2 (0.99) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| Dactinomycin SCHEMBL28161860 | 0.86 | GRB2 (0.98) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| SCHEMBL21090962 | 0.84 | GRB2 (0.94) | GRB2MAPTRECQLSMN1; SMN2HIF1A | |
| SCHEMBL17920644 | 0.84 | GRB2 (0.94) | GRB2MAPTRECQLSMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576921-B2 | Pharmaceutical compositions and methods | POP TEST ONCOLOGY LLC (US) | 2023-02-14 | — | — | US | claimed |
| US-20210154338-A1 | METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY | CORNELL UNIVERSITY | 2021-05-27 | — | — | US | claimed |
| US-20210046147-A1 | COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR | THE PENN STATE RESEARCH FOUNDATION | 2021-02-18 | — | — | US | claimed |
| US-20200101087-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | POP TEST ONCOLOGY LLC | 2020-04-02 | — | — | US | claimed |
| EP-3618867-A1 | METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY | Cornell University (US) | 2020-03-11 | — | — | EP | claimed |
| WO-2018204477-A1 | METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY | CORNELL UNIVERSITY (US) | 2018-11-08 | — | — | WO | claimed |
| EP-2671086-B1 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT | POP TEST ONCOLOGY LLC (US) | 2018-04-25 | — | — | EP | claimed |
| US-20160256517-A1 | COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR | THE PENN STATE RESEARCH FOUNDATION | 2016-09-08 | — | — | US | claimed |
| EP-2671086-A2 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT | Pop Test Cortisol LLC (US) | 2013-12-11 | — | — | EP | claimed |
| US-20130084242-A1 | COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR | THE PENN STATE RESEARCH FOUNDATION (US) | 2013-04-04 | — | — | US | claimed |
| US-20120201747-A1 | System and Method for Diagnosis and Treatment | POP TEST CORTISOL LLC (US) | 2012-08-09 | — | — | US | claimed |
| WO-2012106514-A2 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT | POP TEST CORTISOL LLC (US) | 2012-08-09 | — | — | WO | claimed |
| US-20110123437-A1 | COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR | THE PENN STATE RESEARCH FOUNDATION (US) | 2011-05-26 | — | — | US | claimed |
| EP-1732583-A4 | COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR | PENN STATE RES FOUND (US) | 2009-08-12 | — | — | EP | claimed |
| US-20070053838-A1 | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor | THE PENNSYLVANIA STATE UNIVERSITY | 2007-03-08 | — | — | US | claimed |
| EP-1732583-A1 | COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR | THE PENN STATE RESEARCH FOUNDATION (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005082397-A1 | COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-09-09 | — | — | WO | claimed |
| US-20050191241-A1 | Comprises therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin (opioid growth factor); cancer | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-09-01 | — | — | US | claimed |
| US-20240000980-A1 | METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY | UNIV CORNELL (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2012106514-A2 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT | POP TEST CORTISOL LLC (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201747-A1 | System and Method for Diagnosis and Treatment | MC2R, NR3C1, CRHR1 | GRB2 3723/4885MAPT 3989/4885RECQL 2893/4885 |
| US-20200101087-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | NR3C2, NR3C1, MC2R | GRB2 1127/4885MAPT 1939/4885RECQL 2129/4885 |
| US-11576921-B2 | Pharmaceutical compositions and methods | NR3C2, NR3C1, MC2R | GRB2 1127/4885MAPT 1939/4885RECQL 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.